Beriate (Human Coagulation Factor Viii)

Beriate is a human coagulation factor VIII used to manage bleeding episodes in hemophilia A. This intravenous medication supports blood clotting and is sourced from CSL Behring GmbH in the EU.

Beriate is primarily used to control bleeding in individuals with hemophilia A, a condition where the body lacks sufficient factor VIII to form blood clots. It may also be used before surgeries to prevent excessive bleeding. The medication works by replacing the missing factor VIII, helping the blood to clot properly.

Common effects of Beriate may include mild reactions at the injection site, such as redness or swelling. Some users might experience flu-like symptoms, including fever or chills. Severe allergic reactions are rare but require immediate medical attention.

Beriate should be administered under medical supervision to monitor for adverse reactions. Users with a history of allergic reactions to factor VIII products should exercise caution. Proper storage and handling are essential to maintain the medication's effectiveness.

Beriate may interact with certain medications, including those that affect blood clotting. It is important to inform healthcare providers about all medications being taken to avoid potential interactions. Alcohol consumption should be moderated, as it may influence the medication's effects.